Pure Biologics Tangible Book Value per Share
The Tangible Book Value per Share of Pure Biologics (PUR.WA) as of Oct 9, 2026 is -1.16 PLN. In the previous year, Tangible Book Value per Share was -1.08 PLN — a change of 6.91% (lower).
Get this data via API
Financial Data API
Tangible Book Value per Share
-1.16PLN
YoY
6.91%
Last updated:
The Pure Biologics Tangible Book Value per Share history
3 Years
10 Years
25 Years
Max
| YEAR | Tangible Book Value per Share | YoY |
|---|---|---|
| -1.16PLN | +6.91% | |
| -1.08PLN | -908.86% | |
| 0.13PLN | -90.86% | |
| 1.46PLN | -53.84% | |
| 3.17PLN | -1,090.34% | |
| -0.32PLN | -154.59% | |
| 0.59PLN | +248.93% | |
| 0.17PLN | -3,808.28% | |
| -0.00PLN | -42.33% | |
| -0.01PLN | — |
Pure Biologics Stock analysis
Frequently Asked Questions about Pure Biologics stock
Tangible Book Value per Share of Pure Biologics is -1.16 PLN in 2025.
Tangible Book Value per Share of Pure Biologics changed from -1.08 PLN to -1.16 PLN, representing a 6.91% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Tangible Book Value per Share Pure Biologics since 2006 – with annual values, charts, and detailed analysis.
Tangible book value per share excludes intangible assets and goodwill, providing a more conservative measure of per-share net asset value.
Balance Sheet — Pure Biologics
All Key Metrics — Pure Biologics
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth